Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856141 | 0.85 | PIK3CA (0.41) | ALDH1A1NPSR1ALPLHSD17B10LMNA | |
| SCHEMBL1650420 | 0.83 | ALDH1A1 (0.43) | ALDH1A1NPSR1ALPLHSD17B10LMNA | |
| SCHEMBL26516539 | 0.82 | HSD17B10 (0.36) | HSD17B10MEN1KMT2AHTTNPC1 | |
| SCHEMBL116319 | 0.81 | HSD17B10 (0.35) | ALDH1A1HSD17B10MEN1KMT2AHTT | |
| SCHEMBL20747600 | 0.81 | ALDH1A1 (0.36) | ALDH1A1NPSR1KMT2APIK3CDPIK3CA | |
| SCHEMBL115597 | 0.78 | PTGS1 (0.36) | ALDH1A1NPSR1ALPLLMNAHTT | |
| SCHEMBL20747597 | 0.77 | ALDH1A1 (0.36) | ALDH1A1NPSR1LMNAPIK3CDPIK3CA | |
| SCHEMBL1118864 | 0.77 | SHMT2 (0.33) | HSD17B10MEN1KMT2APIK3CDPIK3CA | |
| SCHEMBL1558035 | 0.76 | CYP3A4 (0.48) | ALDH1A1NPSR1ALPLHSD17B10MEN1 | |
| SCHEMBL1543607 | 0.76 | CCR5 (0.38) | ALDH1A1HSD17B10KMT2AHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-2303886-A2 | PI3K/M TOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | ALDH1A1 4277/4885NPSR1 4651/4885ALPL 4339/4885 |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | ALDH1A1 4256/4885NPSR1 4196/4885ALPL 3547/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | ALDH1A1 4256/4885NPSR1 4196/4885ALPL 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.